Spots Global Cancer Trial Database for A Phase II Study of Anlotinib Combined With Penpulimab in Subjects With Gynecological Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase II Study of Anlotinib Combined With Penpulimab in Subjects With Gynecological Cancer
Official Title: A Single-arm, Open-label, Multi-cohort, Multi-center Phase II Clinical Study of Anlotinib Combined With Penpulimab in the Treatment of Recurrent or Metastatic Gynecological Cancer
Study ID: NCT05028504
Conditions
Study Description
Brief Summary: This is a single-arm, open-label, phase II clinical trial to evaluate the efficacy and safety of penpulimab combined with anlotinib in subjects with gynecological cancer, including 23 ovarian cancer，37 endometrial cancer，26 cervical cancer.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Peking Union Medical College Hospital, Beijing, Beijing, China
The First Affiliated Hospital, Sun Yat-sen University, Guangdong, Guangdong, China
The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, Hefei, China
Shaanxi Provincial Cancer Hospital, Xi'an, Shanxi, China
Shaanxi Provincial People's Hospital, Xi'an, Shanxi, China
Sicchuan cancer hospital, Chengdu, Sichuan, China
Contact Details
Name: Guonan Zhang
Affiliation: Sichuan Cancer Hospital and Research Institute
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
